Investors

Genetic Signatures has released a suite of real-time PCR based products for the routine detection of infectious diseases under the EasyScreen™ brand. This proprietary MDx technology provides hospitals and pathology laboratories with the ability to screen for a wide array of infectious pathogens with a high degree of specificity in a rapid throughput (time to result) environment.

Genetic Signatures’ executive management team combines the scientific skills of the technology developers with the business acumen of industry veterans experienced in critical expansion markets.

For Investor Relations enquiries click link

Receiving your shareholder communications electronically is the best way to stay informed and will assist Genetic Signatures with minimising paper usage. If you haven’t already, we encourage you to make the switch to paperless communications and provide us with your email address. To make the change, login to www.investorserve.com.au, add your email address via ‘My Details’ on the left-hand side of the screen and click ‘Communication Options’ to select the communication options you would like to set to email.

You can make a standing election as to how you would like to receive certain documents including annual reports, meeting-related documents (for example notices of meeting and proxy/voting forms) and payment statements.

You can also make a one-off request to receive a document in physical or electronic form by contacting the registry on [email protected]

You will also be able to access Shareholder Documents such as our Annual Report, Notice of Meeting and other documents relating to shareholder meetings when they are published on our website or made available on the ASX platform.